Amarin shares fell sharply Monday evening after a federal judge ruled that key patents covering its heart drug Vascepa were invalid.

The decision is a victory for two drug makers, Hikma Pharmaceuticals and Dr. Reddy’s Laboratories, seeking to make and sell generic versions of Vascepa.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I know that to many investors yesterday’s district court AMRN ruling seems unfair. And for those of us that own AMRN, it was painful. The judge relied in part on the fact that the advantage of EPA over HDA of reducing TGs but not increasing LDL-C was disclosed in the Mori 2000 reference (https://pubmed.ncbi.nlm.nih.gov/10799369/), and re: secondary factors, the REDUCE-IT trial was not directed at people with TG levels recited in the asserted patent claims. The judge supported her ruling with a 70 page opinion. Given the facts and law, her ruling was not ridiculous.
    However, the battle is not over. I provide biopharma investors insight into the significance of this ruling and the future of this lawsuit (e.g standard of review by the appellate court and time frames) in my post at the link below. I am founder of Amp, and an experienced biotech PhD patent lawyer and biopharma analysist/investor who reviewed the 70 pg DC judge’s opinion in the $AMRN ANDA #Vascepa case.
    https://bit.ly/2UvY1Hq

  • judges are now overstepping their authority in matters after patent approval, should we now sue the patent office ,anyone can make a claim after thefact

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy